Stocktoria
Pulmonx Corp LUNG
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-10-01
Pulmonx Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 74.2% | 74.0% | 73.9% | 74.3% | 73.6% |
| Operating margin | -59.3% | -68.9% | -90.2% | -109.3% | -97.7% |
| Net margin | -59.7% | -67.3% | -88.6% | -109.8% | -100.5% |
| FCF margin | -36.3% | -39.4% | -55.9% | -86.5% | -93.1% |
| Return on assets | -41.8% | -34.6% | -34.2% | -30.4% | -20.7% |
| Return on equity | -99.8% | -65.7% | -51.4% | -38.3% | -25.2% |
| Debt / equity | 0.69× | 0.43× | 0.31× | 0.11× | 0.09× |
| Current ratio | 5.07 | 5.58 | 6.50 | 9.14 | 11.85 |
| Revenue growth | 8.0% | 22.0% | 28.0% | 10.8% | 47.9% |
Source: SEC EDGAR filings · CIK 0001127537 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.